TITLE

SCICLONE'S SCV-07 THERAPY YIELDS GOOD RESULTS FOR TB

PUB. DATE
November 2002
SOURCE
Worldwide Biotech;Nov2002, Vol. 14 Issue 11, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Describes the efficacy of SCV-07, a propriety compound developed by SciClone Pharmaceuticals Inc., in reducing the risk posted by tuberculosis.
ACCESSION #
7692359

 

Related Articles

  • Twister test.  // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p134 

    Reveals that Zandaxin (thymosin) may be useful in treating hepatocellular carcinoma according to a study conducted by SciClone Pharmaceuticals. Information on the study.

  • SCICLONE ENROLLS 500 PATIENTS IN FIRST OF HEPATITIS C TRIALS.  // Biotech Business;Nov2003, Vol. 16 Issue 11, p2 

    Reports on SciClone Pharmaceuticals Incorporated's completion of the planned enrollment of 500 patients in the first of its two phase 3 hepatitis C clinical trials evaluating its lead immune system enhancing drug as of November 2003.

  • About SciClone's Phase 3 Hepatitis C Trials.  // Biotech Business;Nov2003, Vol. 16 Issue 11, p3 

    Provides information on the Phase 3 hepatitis C trials of SciClone Pharmaceuticals Inc.

  • About SciClone.  // Biotech Business;Nov2003, Vol. 16 Issue 11, p4 

    Provides information on biopharmaceutical company SciClone Pharmaceuticals Inc..

  • SCICLONE PHARMACEUTICALS.  // Acquisdata Company SnapShot: Sciclone;8/14/2015, Issue 389, preceding p1 

    The article presents a company profile of Sciclone Pharmaceuticals including information on its financial performance, several pharmaceutical product portfolio for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders, and its competitors...

  • Financings Roundup.  // BioWorld Today;10/6/2010, Vol. 21 Issue 193, p5 

    The article reports on the decision of Silicon Valley Bank to raise the existing debt financing facility of Foster City, California-based SciClone Pharmaceuticals Inc. for its operating subsidiaries.

  • ASCO 2011 Roundup.  // BioWorld Today;6/7/2011, Vol. 22 Issue 109, p12 

    The article reports on the preclinical data presented by SciClone Pharmaceuticals Inc. at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO), which showed that oral mucositis drug SCV-07 inhibits tumors in various xenograft studies that could enhance anticancer treatment.

  • Industry SnapShots.  // Acquisdata Industry SnapShot: China - Biotechnology;11/24/2016, Issue 6413, preceding p1 

    An industry report of the biotechnology industry in China is presented from publisher Acquisdata Pty. Ltd., with topics including the third quarter financial results of SciClone Pharmaceuticals Inc. in 2016, the partnership between WuXi Biologics and Prima and the industry's leading companies.

  • Vaccine Report.  // BioPharm International;Mar2010, Vol. 23 Issue 3, p12 

    The article offers news briefs in the U.S. about Food and Drug Administration's partnership with Seattle, Washington-based international nonprofit organization PATH to formulate advancement in conjugate vaccine and SciClone Pharmaceuticals Inc.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics